Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2017-02-15 Major Shareholding Noti…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
SC 13G/A Filing
Major Shareholding Notification
2017-02-15 English
SC 13G/A Filing
Major Shareholding Notification
2017-02-09 English
Galapagos doses first patient with novel CF corrector GLPG2222
Regulatory Filings Classification · 98% confidence The document is a press release from Galapagos NV announcing the dosing of the first patient in a clinical trial and the receipt of a milestone payment from a collaboration partner (AbbVie). This type of corporate announcement regarding operational milestones, clinical trial progress, and financial impacts from partnerships is classified as a Regulatory Filing (RNS) as it does not fit into specific categories like earnings releases, annual reports, or director dealings.
2017-02-02 English
Galapagos doses first patient with novel CF corrector GLPG2222
Legal Proceedings Report Classification · 99% confidence The document is dated February 1, 2017, and is titled as 'Gereglementeerde informatie' (Regulated information). The content details the start of a Phase 2a clinical study (ALBATROSS) for a drug candidate (GLPG2222) and the submission of an Investigational New Drug (IND) application to the FDA, which triggered a milestone payment. This type of announcement, focusing on clinical trial progress, regulatory milestones, and partnership updates, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it provides specific, time-sensitive operational and financial updates (IND filing, milestone payment, study commencement, expected results date Q4 2017), it fits best as an Earnings Release (ER) which often includes key operational highlights outside of the formal quarterly report (IR). However, given the nature of the announcement being a specific regulatory/clinical update rather than a summary of overall quarterly financial performance, and the presence of the 'Gereglementeerde informatie' header, it strongly suggests a mandatory disclosure. Since it is not a full report (10-K, IR) and is more specific than a general RNS, ER is a strong candidate if it's tied to a reporting period, but the text itself is a press release announcing specific corporate events. In the context of the provided definitions, this is a press release announcing significant operational and partnership milestones. This is often categorized as an Earnings Release (ER) if issued around reporting periods, or a Regulatory Filing (RNS) if it's a standalone disclosure. Given the detail on the clinical trial and partnership payments, it functions as a key operational update, aligning closely with the scope of an ER or a specific announcement. Since it is not a formal report but a press release detailing operational progress and financial milestones, and it is not a proxy/dividend/insider trade notice, 'ER' (Earnings Release - initial announcement of periodical financial results/key highlights) is the most appropriate fit for a significant corporate update of this nature, even if not explicitly tied to a quarterly earnings date.
2017-02-02 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV. Form 6-K is used by foreign private issuers to furnish reports that are required to be made public in their home country or under the rules of the home country exchange. The document includes a press release as an exhibit and references incorporation by reference into registration statements. The document length is 2703 characters, which is relatively short and mainly serves as an announcement of the press release rather than a full report. There is no substantive financial data or detailed report content present. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and often includes Form 6-K submissions.
2017-02-02 English
Galapagos doses first patient with novel CF corrector GLPG2222
Regulatory Filings Classification · 98% confidence The document is a press release from Galapagos NV announcing the dosing of the first patient in a clinical trial and the receipt of a milestone payment from a collaboration partner (AbbVie). This type of corporate announcement regarding operational milestones, clinical trial progress, and financial impacts from partnerships is classified as a Regulatory Filing (RNS) as it does not fit into specific categories like earnings releases, annual reports, or director dealings.
2017-02-01 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.